Thomas Maciag
25Patents
14h-index
27Co-inventors
81Inventor score
Filing activity: Oct 8, 1975 → Aug 22, 2005
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6559119B1 | Method of preparing a tissue sealant-treated biomedical material | Chemistry; Metallurgy | 169 | Expired |
| USRE39321E1 | Supplemented and unsupplemented tissue sealants, methods of their production and use | General | 84 | Expired |
| US7196054B1 | Methods for treating wound tissue and forming a supplemented fibrin matrix | Chemistry; Metallurgy | 71 | Expired |
| US7189410B1 | Supplemented and unsupplemented tissue sealants, methods of their production and use | Chemistry; Metallurgy | 54 | Expired |
| US6716974B1 | Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids | Human Necessities | 47 | Expired |
| US4443546A | Process and composition for propagating mammalian cells | Chemistry; Metallurgy | 46 | Expired |
| US5723282A | Method of preparing organs for vitrification | Human Necessities | 46 | Expired |
| US7229959B1 | Supplemented fibrin matrix delivery systems | Chemistry; Metallurgy | 36 | Expired |
| US4868113A | Recombinant DNA vector encoding human endothelial cell growth factor | Emerging Cross-Sectional Technologies | 33 | Expired |
| US6433138B1 | Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids | Human Necessities | 30 | Expired |
| US6982170B1 | Compositions, methods and kits relating to thrombin degradation resistant fibroblast growth factor-1 | Chemistry; Metallurgy | 25 | Expired |
| USRE39192E1 | Supplemented and unsupplemented tissue sealants, methods of their production and use | General | 25 | Expired |
| US6187529A | Method for preparing organs for transplantation after cryopreservation | Human Necessities | 16 | Expired |
| USRE39298E1 | Supplemented and unsupplemented tissue sealants, methods of their production and use | General | 16 | Expired |
| US4165258A | Plasminogen activating enzyme-specific competitive inhibitor | Emerging Cross-Sectional Technologies | 12 | Expired |
| US5962214A | Method of preparing tissues and cells for vitrification | Human Necessities | 11 | Expired |
| US5552528A | Bovine b-endothelial cell growth factor | Emerging Cross-Sectional Technologies | 8 | Expired |
| US6825007B2 | Therapeutic and diagnostic methods and compositions based on Jagged/Notch proteins and nucleic acids | Human Necessities | 8 | Expired |
| US5827826A | Compositions of human endothelial cell growth factor | Emerging Cross-Sectional Technologies | 4 | Expired |
| US7304138B2 | Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids | Human Necessities | 3 | Expired |
| US5571790A | Recombinant human endothelial cell growth factor | Emerging Cross-Sectional Technologies | 3 | Expired |
| US5849538A | DNA encoding human endothelial cell growth factors and plasmids comprising said DNA | Emerging Cross-Sectional Technologies | 1 | Expired |
| US7501281B2 | Compositions, methods and kits related to thrombin, Notch signaling and stamatogenesis and growth of stem cells | Chemistry; Metallurgy | 1 | Active |
| USRE37850E1 | Recombinant human endothelial cell growth factor | General | 0 | Expired |
| USRE38240E1 | DNA encoding human endothelial cell growth factors and plasmids comprising said DNA | General | 0 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.